| Literature DB >> 27006319 |
Thiago Gagliano-Jucá1, Mauro Napolitano2, Fernanda Del Grossi Ferraz Carvalho3, Rafael Campos3, Fabíola Zakia Mónica3, Mário Angelo Claudino3, Edson Antunes3, Anibal Gil Lopes1, Gilberto De Nucci4.
Abstract
INTRODUCTION: Hydrochlorothiazide has a negative influence on penile erection but little is known about the mechanism(s) involved. AIMS: To characterize the effects of this diuretic on mouse corpus cavernosum (CC) smooth muscle in vitro and ex vivo.Entities:
Keywords: Adrenergic Mechanism; Corpus Cavernosum; Diuretics; Erectile Dysfunction
Year: 2016 PMID: 27006319 PMCID: PMC5005312 DOI: 10.1016/j.esxm.2016.02.003
Source DB: PubMed Journal: Sex Med ISSN: 2050-1161 Impact factor: 2.491
Figure 1Response curves of mouse corpus cavernosum smooth muscle strips to PE and electrical field stimulation. Panel A shows the addition of PE to corpus cavernosum strips alone (control) or after pre-incubation with HTZ (10–100 μmol/L). Panel B shows the addition of PE to corpus cavernosum strips alone or after pre-incubation with HTZ (100 μmol/L), indomethacin (5 μmol/L), or HTZ plus indomethacin. Panel C shows the addition of PE to corpus cavernosum strips alone or after pre-incubation with HTZ (100 μmol/L), L-NAME (100 μmol/L), or HTZ plus L-NAME. Panel D shows contractile responses of mouse corpus cavernosum to electrical field stimulation (1–32 Hz) in the absence (control) or presence of HTZ (100 μmol/L). PE was used at concentrations of 10 nmol/L to 100 μmol/L. Contraction values were calculated by subtracting the basal tone from maximal contractions (milli-newtons) produced by PE or electrical field stimulation. Data are presented as mean ± standard error of the mean of four to eight experiments. ∗P < .05 vs control for each frequency evaluated. HTZ = hydrochlorothiazide; L-NAME = N(ω)-nitro-L-arginine methyl ester; PE = phenylephrine.
pEC50 and Emax obtained from concentration-response curves to phenylephrine (10 nmol/L–100 μmol/L) with and without diuretics in mouse corpus cavernosum smooth muscle∗
| Phenylephrine | |||
|---|---|---|---|
| pEC50 | Emax (mN) | Experiments, n | |
| Control | 6.20 ± 0.15 | 0.44 ± 0.05 | 8 |
| HTZ 10 μmol/L | 6.31 ± 0.11 | 0.54 ± 0.06 | 6 |
| HTZ 30 μmol/L | 6.56 ± 0.04 | 0.69 ± 0.02 | 4 |
| HTZ 100 μmol/L | 6.37 ± 0.11 | 0.72 ± 0.07‡ | 7 |
| Control | 6.04 ± 0.03 | 0.44 ± 0.05 | 7 |
| Amiloride 100 μmol/L | 5.46 ± 0.07‡ | 0.44 ± 0.05 | 4 |
| Control | 5.54 ± 0.16 | 0.53 ± 0.04 | 5 |
| HTZ 100 μmol/L | 5.27 ± 0.16 | 0.70 ± 0.05 | 8 |
| HTZ 100 μmol/L + amiloride 100 μmol/L | 4.94 ± 0.12† | 0.53 ± 0.04‖ | 13 |
| Control | 6.33 ± 0.10 | 0.48 ± 0.06 | 10 |
| Long-term HTZ (6 mg/kg/d) | 6.38 ± 0.11 | 0.77 ± 0.10 | 4 |
| Control | 6.10 ± 0.15 | 0.47 ± 0.07 | 5 |
| Long-term HTZ + amiloride | 6.14 ± 0.17 | 0.53 ± 0.07 | 5 |
Emax = maximal response; HTZ = hydrochlorothiazide; pEC50 = potency at half-maximal effective concentration.
Data presented as mean ± standard error of the mean of the number of experiments. pEC50 is represented as the negative logarithm of molar concentration to produce 50% of maximal contractile response elicited by the agonist relative to phenylephrine-induced contractions. Emax is calculated as milli-newtons of contraction relative to the maximal changes from the contractile response produced by phenylephrine.
P < .05 vs control group; ‡P < .01 vs control group; ‖P < .05 vs HTZ group.
pEC50 and Emax obtained from concentration-response curves to phenylephrine (10 nmol/L–100 μmol/L) with and without HTZ (100 μmol/L), L-NAME, and indomethacin in mouse cavernosal smooth muscle∗
| Phenylephrine | |||
|---|---|---|---|
| pEC50 | Emax (mN) | Experiments, n | |
| Control | 6.24 ± 0.14 | 0.46 ± 0.02 | 7 |
| L-NAME 100 μmol/L | 6.89 ± 0.14‡ | 0.65 ± 0.05 | 7 |
| HTZ 100 μmol/L | 6.20 ± 0.13 | 0.61 ± 0.02 | 7 |
| HTZ 100 μmol/L + L-NAME 100 μmol/L | 6.79 ± 0.16† | 0.60 ± 0.04 | 7 |
| Control | 6.25 ± 0.14 | 0.46 ± 0.02 | 5 |
| Indomethacin 5 μmol/L | 5.69 ± 0.11† | 0.48 ± 0.02 | 7 |
| HTZ 100 μmol/L | 6.37 ± 0.11 | 0.70 ± 0.02 | 7 |
| HTZ 100 μmol/L + indomethacin 5 μmol/L | 6.19 ± 0.05§ | 0.60 ± 0.05 | 7 |
Emax = maximal response; HTZ = hydrochlorothiazide; L-NAME = N(ω)-nitro-L-arginine methyl ester; pEC50 = potency at half-maximal effective concentration.
Data presented as mean ± standard error of the mean of the number of experiments. pEC50 is represented as the negative logarithm of molar concentration to produce 50% of maximal contractile response elicited by an agonist relative to phenylephrine-induced contractions. Emax is calculated as milli-newtons of contraction relative to the maximal changes from the contractile response produced by phenylephrine.
P < .05 vs control group; ‡P < .01; §P < .05 vs indomethacin group.
Figure 2Concentration-response curves of mouse corpus cavernosum smooth muscle strips to PE and relaxant response to electrical field stimulation after long-term administration of HTZ in vivo. Panel A shows the addition of PE to corpus cavernosum strips from untreated (control) and HTZ-treated mice. Panel B shows the relaxant responses to electrical field stimulation (1–32 Hz) in untreated (control) and HTZ-treated animals. ∗P < .05 vs control for each frequency evaluated. PE was used at concentrations of 10 nmol/L to 100 μmol/L. Contraction values were calculated by subtracting the basal tone from maximal contractions (milli-newtons) produced by PE or electrical field stimulation. Data are presented as mean ± standard error of the mean of 4 to 10 experiments. HTZ = hydrochlorothiazide; PE = phenylephrine.
Figure 3Concentration-response curves of mouse corpus cavernosum smooth muscle strips to PE in the presence of Am. Panel A shows the addition of PE to corpus cavernosum strips alone (control) and after pre-incubation with Am (100 μmol/L). Panel B shows the addition of PE to corpus cavernosum strips alone and after pre-incubation with HTZ (100 μmol/L) or HTZ + Am. PE was used at concentrations of 10 nmol/L to 100 μmol/L. Contraction values were calculated by subtracting the basal tone from maximal contractions (milli-newtons) produced by PE. Data are presented as mean ± standard error of the mean of 4 to 13 experiments. Am = amiloride; HTZ = hydrochlorothiazide; PE = phenylephrine.
Figure 4Concentration-response curves of mouse corpus cavernosum smooth muscle strips to PE and relaxant response to electrical field stimulation after long-term coadministration of HTZ and amiloride in vivo. Panel A shows the addition of PE to corpus cavernosum strips from untreated mice (control) and mice treated with HTZ plus amiloride. Panel B shows relaxant responses to electrical field stimulation (1–32 Hz) in untreated mice (control) and mice treated with HTZ plus amiloride. PE was used at concentrations of 10 nmol/L to 100 μmol/L. Contraction values were calculated by subtracting the basal tone from maximal contractions (milli-newtons) produced by PE or electrical field stimulation. Data are presented as mean ± standard error of the mean of five experiments. CTL = control; HTZ = hydrochlorothiazide; PE = phenylephrine.
Figure 5RT polymerase chain reaction with cDNA from mouse tissues (n = 2). Reactions were produced with (+) and without (−) RT. The genes (corresponding encoded proteins) under study appear below the respective gels. CC = corpus cavernosum; ENaC = epithelial sodium channel; K = kidney; NCC = NaCl cotransporter; RT = reverse transcriptase.
Figure 6Evaluation of ROCK activity. Panel A shows the influence of HTZ (100 μmol/L), Am (100 μmol/L), HTZ + Am, and Y-27632 on ROCK activity, expressed as the mean percentage of control ± standard error of the mean. Control = 100 ± 4.0; HTZ = 92 ± 3.7; HTZ + Am = 78 ± 3.8; Am = 82 ± 3.7; Y-27632 = 28 ± 1.5. ∗P < .01 vs control group; †P < .001 vs control group; n = 6 for all groups. Panel B shows total ROCK activity, expressed as mean percentage ± standard error of the mean compared with the control group. Control = 100 ± 5.7%; HTZ = 89 ± 7.0%; HTZ + Am = 76 ± 5.3%. ∗P < .01 vs control group; n = 7 for all groups. Am = amiloride; HTZ = hydrochlorothiazide; ROCK = Rho-kinase.
Abundance of transcripts of Rock1, Rock2, Nos1, Nos3, Gucy1a3, Pde5a, and Prkg1 in mouse corpora cavernosa∗
| Fold change in gene expression | |||
|---|---|---|---|
| Gene name | Control group | HTZ group | HTZ + Am group |
| Rock1 | 1.01 ± 0.11 | 1.11 ± 0.15 | 0.61 ± 0.06 |
| Rock2 | 1.02 ± 0.15 | 0.91 ± 0.29 | 1.0 ± 0.19 |
| Nos1 | 1.0 ± 0.09 | 0.8 ± 0.19 | 0.45 ± 0.1 |
| Nos3 | 1.0 ± 0.05 | 1.08 ± 0.13 | 0.87 ± 0.06 |
| Gucy1a3 | 1.0 ± 0.08 | 0.97 ± 0.23 | 0.93 ± 0.16 |
| Pde5a | 1.0 ± 0.04 | 0.79 ± 0.01† | 0.98 ± 0.12 |
| Prgk1 | 1.0 ± 0.05 | 0.91 ± 0.06 | 0.99 ± 0.22 |
Control = untreated mice; HTZ = mice treated with hydrochlorothiazide; HTZ + Am = mice treated with hydrochlorothiazide plus amiloride.
Messenger RNA levels were analyzed by quantitative real-time polymerase chain reaction and normalized in relation to those of the HPRT gene. Average values ± standard error of the mean of three independent biological replicas are represented.
P < .05 vs control group.